Evaluating a new imaging technique for monitoring prostate cancer in men on active surveillance
ESCAPE - Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate Cancer
This study is looking at how a special imaging test called PSMA PET-CT can help doctors better monitor prostate cancer in men who are being watched closely instead of treated right away, with the goal of reducing unnecessary treatments and side effects for those with low-risk cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11052535 on NIH RePORTER |
What this research studies
This research investigates the use of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography (PSMA PET-CT) to improve the monitoring of prostate cancer in men who are on active surveillance. The study aims to optimize the protocols for active surveillance by assessing the accuracy of PSMA PET-CT in detecting clinically significant prostate cancer compared to traditional methods like biopsies and PSA measurements. By focusing on minimizing unnecessary treatments and their associated side effects, the research seeks to enhance patient care and outcomes for those with low-risk prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with low-risk prostate cancer who are currently on active surveillance.
Not a fit: Patients with high-risk prostate cancer or those who have already undergone definitive treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate monitoring of prostate cancer, reducing unnecessary treatments and improving quality of life for patients.
How similar studies have performed: Previous research has shown that advanced imaging techniques like MRI can improve detection rates of clinically significant prostate cancer, suggesting potential success for this novel approach.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Mcclure, Timothy — Weill Medical Coll of Cornell Univ
- Study coordinator: Mcclure, Timothy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.